PAVmed Historical Income Statement
| PAVMZ Stock | USD 0 0 30.00% |
Historical analysis of PAVmed Series income statement accounts such as Total Operating Expenses of 78.3 M, Depreciation And Amortization of 3.5 M, Tax Provision of 0.0 or Interest Income of 431.8 K can show how well PAVmed Series Z performed in making a profits. Evaluating PAVmed Series income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of PAVmed Series's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining PAVmed Series Z latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PAVmed Series Z is a good buy for the upcoming year.
PAVmed |
About PAVmed Income Statement Analysis
PAVmed Series Z Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to PAVmed Series shareholders. The income statement also shows PAVmed investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
PAVmed Series Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of PAVmed Series Z. It is also known as PAVmed Series overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from PAVmed Series' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into PAVmed Series Z current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Series Z. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At this time, PAVmed Series' Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 37.4 M in 2025, despite the fact that Operating Income is likely to grow to (58.8 M).
PAVmed Series income statement Correlations
Click cells to compare fundamentals
PAVmed Series Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PAVmed Series income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 53K | 5.8M | 1.3M | 589K | 677.4K | 1.2M | |
| Selling General Administrative | 12.4M | 25.6M | 41.0M | 30.9M | 35.6M | 37.4M | |
| Operating Income | (23.4M) | (54.4M) | (90.9M) | (68.8M) | (61.9M) | (58.8M) | |
| Income Before Tax | (35.9M) | (56.1M) | (103.2M) | (79.3M) | (71.3M) | (67.8M) | |
| Net Income | (34.3M) | (50.3M) | (101.3M) | (64.2M) | (57.8M) | (54.9M) | |
| Other Operating Expenses | 23.4M | 54.9M | 91.3M | 71.2M | 81.9M | 86.0M | |
| Ebit | (35.8M) | (56.1M) | (102.0M) | (78.7M) | (70.8M) | (67.3M) | |
| Research Development | 11.0M | 19.8M | 25.5M | 14.3M | 16.4M | 10.6M | |
| Ebitda | (35.8M) | (55.9M) | (99.4M) | (75.7M) | (68.2M) | (64.8M) | |
| Total Operating Expenses | 23.4M | 54.3M | 87.7M | 64.8M | 74.6M | 78.3M | |
| Depreciation And Amortization | 23K | 226K | 2.6M | 2.9M | 3.4M | 3.5M | |
| Total Other Income Expense Net | (12.5M) | (1.7M) | (12.2M) | (10.5M) | (9.4M) | (9.0M) | |
| Net Interest Income | (713K) | (523K) | (1.3M) | (448K) | (515.2K) | (541.0K) | |
| Interest Income | 5.6M | 591.3K | 169K | 505K | 454.5K | 431.8K | |
| Gross Profit | (23K) | (85K) | (3.2M) | (4.0M) | (3.6M) | (3.4M) | |
| Net Income From Continuing Ops | (35.9M) | (56.1M) | (103.2M) | (86.4M) | (77.8M) | (73.9M) | |
| Reconciled Depreciation | 23K | 226K | 2.5M | 2.9M | 3.4M | 3.5M | |
| Income Tax Expense | (1.6M) | (5.8M) | (1.9M) | (13.0B) | (11.7B) | (11.1B) | |
| Minority Interest | (1.6M) | 5.8M | 14.3M | 15.8M | 18.2M | 19.1M | |
| Cost Of Revenue | 23K | 585K | 3.6M | 6.4M | 7.4M | 7.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PAVmed Stock Analysis
When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.